重组p53基因腺病毒注射液胸腔灌注治疗恶性胸水的临床疗效观察  

Effects of recombinant adenovirus p53 injection on malignant pleural effusion

作　　者：陈萍[1] 胡中华[1] 胡义德[1] 张明慧[1] 李莎莎[1] 周俊[1] 蒋莉[1] 潘杰[1] 

机构地区：[1]第三军医大学新桥医院全军肿瘤诊治研究所肿瘤三病区,重庆400037

出　　处：《西部医学》2010年第4期635-636,共2页Medical Journal of West China

摘　　要：目的观察重组p53基因腺病毒(rAd-p53)注射液胸腔灌注治疗恶性胸水的临床疗效。方法45例恶性胸水患者均行胸腔穿刺彻底引流后通过胸腔闭式引流管灌注rAd-p53,用量为1×1012VP×2支,4周后根据胸水量的变化进行疗效评价。结果45例患者中完全缓解(CR)20例,部分缓解(PR)19例,稳定(SD)4例,进展(PD)2例,总有效率达86.7%(39/45)。达到CR的20例病人中,有16例病人胸水在3个月内没有再出现。各肿瘤病种之间没有差异。所有患者主要副反应为自限性发热,体温在37.5℃~39.1℃之间,12h^24h后均可自行恢复正常。结论rAd-p53注射液胸腔灌注治疗恶性胸水的有效率高、疗效确切、副作用可以耐受,值得临床进一步应用观察。Objective To evaluate the effects of recombinant adenovirus p53 injection （rAd-p53,Gendicine） on malignant pleural effusion. Methods 2 × 10^12 VP of rAd-p53 was treated through intrathorakcic drain after malignant pleural effusion drain away for 45 cases. Therapeutic evaluation was carried out after 4 weeks according to the alteration of pleural effusion. Results Total effective rate was 86.7% （39/45）in 45 cases of malignant pleural effusion, included 20 cases in complete remission, 10 cases in partial remission, 4 cases in stable, and 2 cases in progress. 16 patients were norelapse after 3 months in 20 eases of complete remission. No difference in each kind of tumor patients. Side effects was self-limited fever between 37.5℃～39. 1℃. fadeaway after 12h～24h. Conclusion The rAd-p53 was effective and tolerant to treat patients with malignant pleural effusion.

关 键 词：p53基因腺病毒注射液 恶性胸水 胸腔灌注 疗效 副反应 

分 类 号：R730.5[医药卫生—肿瘤]